세계의 전이성 암 치료제 시장 : 치료법별, 적응증별, 유통 채널별 - 기회 분석 및 산업 예측(2023-2032년)

Metastatic Cancer Drugs Market By Therapy, By Indication, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,064,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,512,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

전이성 암 치료제(Metastatic Cancer Drugs) 시장은 2022년 677억 달러였으며, 2023년부터 2032년에 걸쳐 CAGR 7.3%로 추이하며 성장할 것으로 예상되며, 2032년에는 1,369억 달러에 이를 것으로 추정됩니다.

전이성 암은 4기 암이라고도 하며 원래 부위(원발 종양)에서 신체의 다른 부위로 퍼진 암을 설명하는 데 사용되는 용어입니다. 암세포가 주변 조직을 침범하고 혈류 또는 림프계로 들어가 다른 위치에 새로운 종양을 형성하는 능력은 전이성 암의 복잡성에 기여합니다. 전이성 암에 대한 일반적인 치료법에는 화학 요법, 호르몬 요법, 표적 요법 및 면역 요법과 같은 전신 요법이 포함됩니다.

또한 전이성 암은 유방암, 폐암, 결장암, 전립선암, 흑색종 등 다양한 유형의 원발성 종양에서 발생할 수 있습니다. 가장 흔한 전이 부위로는 폐, 간, 뼈, 뇌, 림프절 등이 있습니다. 또한 전이성 암은 국소 암보다 더 심각하고 어려운 단계로 간주됩니다. 전이암은 예후가 나쁘고 치료 옵션이 줄어드는 것과 관련이 있습니다. 암세포가 먼 부위로 퍼지면 질병을 완전히 근절하기가 어렵습니다. 전이성 암의 증상과 징후는 전이의 위치와 크기에 따라 다릅니다. 일반적인 증상으로는 체중 감소, 특정 부위의 지속적인 통증, 호흡 곤란, 피로감, 뇌가 영향을 받는 경우 신경학적 증상 등이 있습니다.

전이성 암 치료제 시장의 성장을 이끄는 주요 요인은 R&D의 발전, 전이성 암 유병률 증가, 맞춤형 의약품에 대한 수요 급증, 노인 인구 증가, 정부 지원 이니셔티브입니다. 전 세계적으로 전이성 암의 발생률과 유병률이 급증하는 것은 시장 성장의 중요한 동인으로 작용합니다. 예를 들어, 2022년 유방암 연구 재단(BCRF)에서 발표한 기사에 따르면 미국에서 6-10%의 여성이 4기 유방암 진단을 받고, 초기 유방암 진단을 받은 여성의 거의 30%가 전이성 유방암을 앓을 수 있다고 합니다. 전이성 암 진단을 받는 사람의 수가 급증함에 따라 진행성 질환과 관련된 특정 문제를 해결할 수 있는 효과적인 약물의 개발과 공급이 필요합니다.

또한 지속적인 R&D 노력은 전이성 암 치료제 시장 성장을 주도하는 데 중요한 역할을 합니다. 분자 생물학, 유전체학 및 표적 치료법의 발견으로 전이를 유발하는 분자 메커니즘을 구체적으로 표적으로 하는 혁신적인 약물이 개발되었습니다. 신약 발견 기술의 발전으로 새로운 약물 표적을 식별하고 이러한 표적을 선택적으로 억제하는 화합물을 개발하여 효능을 개선하고 독성을 줄였습니다. 예를 들어, 티로신 키나아제 억제제(TKI)와 같은 표적 치료제는 암 성장 및 진행에 관여하는 특정 분자 표적을 억제하여 특정 유형의 전이성 암을 치료하는 데 괄목할 만한 성공을 거두었습니다. 이러한 발전으로 인해 시장에서 더 새롭고 효과적인 약물에 대한 수요가 증가하고 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향 요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진 요인
    • 암의 검출과 진단의 발달
    • 전이성 암의 유병률 증가
    • 맞춤형 의료의 채택 급증
  • 억제 요인
    • 항암제 사용에 따른 부작용
  • 기회
    • 미개발 신흥국에서 높은 성장 가능성
    • 파이프라인 의약품 증가
• COVID-19에 의한 시장에 대한 영향 분석

제4장 전이성 암 치료제 시장 : 치료법별

• 화학요법
• 호르몬요법
• 표적요법
• 면역요법

제5장 전이성 암 치료제 시장 : 적응증별

• 유방암
• 폐암
• 전립선암
• 대장암
• 흑색종
• 기타

제6장 전이성 암 치료제 시장 : 유통 채널별

• 병원 약국
• 약국 및 소매 약국
• 온라인 제공업체

제7장 전이성 암 치료제 시장 : 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아 태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타 아시아 태평양
• 남미·중동·아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타 지역

제8장 경쟁 구도

• 소개
• 주요 성공 전략
• 주요 10기업의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제9장 기업 개요

• Bristol-Myers Squibb Company
• Merck&Co., Inc.
• AstraZeneca plc
• Novartis AG
• Eli Lilly and Company.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson&Johnson
• Amgen Inc.
• Sanofi SA

LYJ

영문 목차

영문목차

According to a new report published by Allied Market Research, titled, "Metastatic Cancer Drugs Market," The metastatic cancer drugs market was valued at $67.7 billion in 2022, and is estimated to reach $136.9 billion by 2032, growing at a CAGR of 7.3% from 2023 to 2032. Metastatic cancer, also referred to as stage IV cancer, is a term used to describe cancer that has spread from its original site (primary tumor) to other parts of the body. The ability of cancer cells to invade nearby tissues, enter the bloodstream or lymphatic system, and establish new tumors in different locations contributes to the complexity of metastatic cancer. Common treatment approaches for metastatic cancer include systemic therapies such as chemotherapy, hormonal therapy, targeted therapy and immunotherapy.

Moreover, metastatic cancer can arise from various types of primary tumors such as breast, lung, colon, prostate, and melanoma. The most common sites of metastasis include the lungs, liver, bones, brain, and lymph nodes. In addition, metastatic cancer is considered as more severe and challenging stage than localized cancer. It is associated with poorer prognosis and reduced treatment options. The spread of cancer cells to distant sites makes it difficult to eradicate the disease completely. The symptoms and signs of metastatic cancer vary depending on the location and size of the metastasis. Common symptoms may include weight loss, persistent pain in specific areas, shortness of breath, fatigue, and neurological symptoms if the brain is affected.

The major factors that drive the growth of metastatic cancer drugs market are advancements in R&D, increase in prevalence of metastatic cancer, surge in demand for personalized medicine, rise in geriatric population, and supportive government initiatives. The surge in incidence and prevalence of metastatic cancer worldwide serves as a significant driver for market growth. For instance, an article published by Breast Cancer Research Foundation (BCRF) in 2022, stated that, 6 to 10% of women are diagnosed with stage 4 breast cancer in the U.S., and nearly 30 percent of women diagnosed with early-stage breast cancer may suffer from metastatic stage cancer. The upsurge in number of individuals diagnosed with metastatic cancer necessitates the development and availability of effective drugs to address the specific challenges associated with advanced stage disease.

Further, ongoing R&D efforts play a crucial role in driving the metastatic cancer drugs market growth. Discoveries in molecular biology, genomics, and targeted therapies have led to the development of innovative drugs that specifically target the molecular mechanisms driving metastasis. Advancements in drug discovery techniques have led to the identification of new drug targets and the development of compounds that selectively inhibit these targets, leading to improved efficacy and reduced toxicity. For instance, targeted therapies, such as tyrosine kinase inhibitors (TKIs), have shown remarkable success in treating specific types of metastatic cancers by inhibiting specific molecular targets involved in cancer growth and progression. These advancements drive the demand for newer and more effective drugs in the market.

In addition, R&D efforts have focused on developing combination therapies involving the simultaneous use of multiple drugs with complementary mechanisms of action. Combination therapies can enhance treatment response, overcome drug resistance, and improve patients' outcomes. Furthermore, development of novel drug delivery systems enhances the efficacy and safety of metastatic cancer drugs. Advanced drug delivery technologies such as nanotechnology-based formulations, targeted drug delivery systems, and combination therapies enable better drug targeting, reduced toxicity, and improved treatment outcomes. These innovations contribute to the growth of the metastatic cancer drugs market. Moreover, government initiatives such as funding for research, development, and accessibility of metastatic cancer drugs is anticipated to propel the market growth. Public funding, grants, and collaborations with academic institutions and pharmaceutical companies facilitate the discovery and development of novel drugs and treatment approaches. These initiatives aim to improve patient access to affordable metastatic cancer drugs, further driving the market growth.

In addition, increased awareness and education about metastatic cancer and its treatment options contribute to the market growth. Patient and caregiver advocacy groups, awareness campaigns, and educational programs help in promoting early detection, timely diagnosis, and appropriate treatment for metastatic cancer. This heightened awareness drives the demand for metastatic cancer drugs and improves patient outcomes. The metastatic cancer drugs market is segmented on the basis of therapy, indication, distribution channel, and region. On the basis of therapy, the market is categorized into chemotherapy, hormonal therapy, targeted therapy, and immunotherapy. On the basis of indication, the market is classified into breast cancer, lung cancer, prostate cancer, colorectal cancer, melanoma, and others. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global metastatic cancer drugs market are Novartis AG, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Amgen Inc., Sanofi S.A. and F. Hoffmann-La Roche Ltd. The key players have adopted strategies such as collaboration, product launch, new product development, and product approval to expand their product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the metastatic cancer drugs market analysis from 2022 to 2032 to identify the prevailing metastatic cancer drugs market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the metastatic cancer drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global metastatic cancer drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapy

• Chemotherapy
• Hormonal therapy
• Targeted therapy
• Immunotherapy

By Indication

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma
• Others

By Distribution channel

• Hospital Pharmacies
• Drug Store and Retail Pharmacies
• Online Providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Amgen Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Eli Lilly and Company.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. High bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. High bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Advancements in cancer detection and diagnosis
    • 3.4.1.2. Increase in prevalence of metastatic cancer
    • 3.4.1.3. Surge in adoption of personalized medicine

• 3.4.2. Restraints
  • 3.4.2.1. Adverse effects associated with the use of cancer drugs

• 3.4.3. Opportunities
  • 3.4.3.1. High growth potential in untapped emerging economies
  • 3.4.3.2. Increase in number of pipeline drugs

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: METASTATIC CANCER DRUGS MARKET, BY THERAPY

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Chemotherapy
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Hormonal therapy
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Targeted therapy
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Immunotherapy
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: METASTATIC CANCER DRUGS MARKET, BY INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Breast Cancer
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Lung Cancer
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Prostate Cancer
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Colorectal Cancer
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Melanoma
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country
• 5.7. Others
  • 5.7.1. Key market trends, growth factors and opportunities
  • 5.7.2. Market size and forecast, by region
  • 5.7.3. Market share analysis by country

CHAPTER 6: METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Drug Store and Retail Pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Providers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: METASTATIC CANCER DRUGS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Therapy
  • 7.2.3. Market size and forecast, by Indication
  • 7.2.4. Market size and forecast, by Distribution channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Therapy
    • 7.2.5.1.3. Market size and forecast, by Indication
    • 7.2.5.1.4. Market size and forecast, by Distribution channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Therapy
    • 7.2.5.2.3. Market size and forecast, by Indication
    • 7.2.5.2.4. Market size and forecast, by Distribution channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Therapy
    • 7.2.5.3.3. Market size and forecast, by Indication
    • 7.2.5.3.4. Market size and forecast, by Distribution channel
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Therapy
  • 7.3.3. Market size and forecast, by Indication
  • 7.3.4. Market size and forecast, by Distribution channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Therapy
    • 7.3.5.1.3. Market size and forecast, by Indication
    • 7.3.5.1.4. Market size and forecast, by Distribution channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Therapy
    • 7.3.5.2.3. Market size and forecast, by Indication
    • 7.3.5.2.4. Market size and forecast, by Distribution channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Therapy
    • 7.3.5.3.3. Market size and forecast, by Indication
    • 7.3.5.3.4. Market size and forecast, by Distribution channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Therapy
    • 7.3.5.4.3. Market size and forecast, by Indication
    • 7.3.5.4.4. Market size and forecast, by Distribution channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Therapy
    • 7.3.5.5.3. Market size and forecast, by Indication
    • 7.3.5.5.4. Market size and forecast, by Distribution channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Therapy
    • 7.3.5.6.3. Market size and forecast, by Indication
    • 7.3.5.6.4. Market size and forecast, by Distribution channel
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Therapy
  • 7.4.3. Market size and forecast, by Indication
  • 7.4.4. Market size and forecast, by Distribution channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Therapy
    • 7.4.5.1.3. Market size and forecast, by Indication
    • 7.4.5.1.4. Market size and forecast, by Distribution channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Therapy
    • 7.4.5.2.3. Market size and forecast, by Indication
    • 7.4.5.2.4. Market size and forecast, by Distribution channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Therapy
    • 7.4.5.3.3. Market size and forecast, by Indication
    • 7.4.5.3.4. Market size and forecast, by Distribution channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Key market trends, growth factors and opportunities
    • 7.4.5.4.2. Market size and forecast, by Therapy
    • 7.4.5.4.3. Market size and forecast, by Indication
    • 7.4.5.4.4. Market size and forecast, by Distribution channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Key market trends, growth factors and opportunities
    • 7.4.5.5.2. Market size and forecast, by Therapy
    • 7.4.5.5.3. Market size and forecast, by Indication
    • 7.4.5.5.4. Market size and forecast, by Distribution channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Key market trends, growth factors and opportunities
    • 7.4.5.6.2. Market size and forecast, by Therapy
    • 7.4.5.6.3. Market size and forecast, by Indication
    • 7.4.5.6.4. Market size and forecast, by Distribution channel
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Therapy
  • 7.5.3. Market size and forecast, by Indication
  • 7.5.4. Market size and forecast, by Distribution channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Therapy
    • 7.5.5.1.3. Market size and forecast, by Indication
    • 7.5.5.1.4. Market size and forecast, by Distribution channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Therapy
    • 7.5.5.2.3. Market size and forecast, by Indication
    • 7.5.5.2.4. Market size and forecast, by Distribution channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Key market trends, growth factors and opportunities
    • 7.5.5.3.2. Market size and forecast, by Therapy
    • 7.5.5.3.3. Market size and forecast, by Indication
    • 7.5.5.3.4. Market size and forecast, by Distribution channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Key market trends, growth factors and opportunities
    • 7.5.5.4.2. Market size and forecast, by Therapy
    • 7.5.5.4.3. Market size and forecast, by Indication
    • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Bristol-Myers Squibb Company
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Merck & Co., Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. AstraZeneca plc
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Novartis AG
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Eli Lilly and Company.
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Pfizer Inc.
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. F. Hoffmann-La Roche Ltd.
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Johnson & Johnson
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Amgen Inc.
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Sanofi S.A.
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance

관련자료